{
    "nct_id": "NCT05006794",
    "official_title": "A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies",
    "inclusion_criteria": "General Inclusion Criteria (all cohorts):\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Measurable disease per RECIST version 1.1\n* Adequate hematology, renal and hepatic function\n* Left ventricular ejection fraction (LVEF) ≥ 50%\n* Patients with brain metastases may be enrolled only if treated, nonprogressive, asymptomatic and not taking high dose steroids for at least 4 weeks prior to Cycle 1 Day 1 (C1D1)\n* Individuals of childbearing potential who engage in heterosexual intercourse must agree to use method(s) of contraception, per protocol.\n* Tissue criteria: must provide sufficient, and adequate tumor tissue sample or agree to have a biopsy taken.\n\nPart A Specific Inclusion Criteria: zamzetoclax as monotherapy\n\n* Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumor for which no standard therapy is available, standard therapy has failed, or for whom standard-of-care therapy is contraindicated.\n\nCohorts B1 and C1 Specific Inclusion Criteria:\n\n* Histologically or cytologically confirmed unresectable metastatic or locally advanced disease following treatment for metastatic disease including an immune checkpoint inhibitor and a platinum-containing chemotherapy\n* Patients with actionable genomic alterations must have also received treatment with at least 1 approved therapy appropriate to the genomic alteration unless unavailable or contraindicated\n\nCohorts B4 and C4 Specific Inclusion Criteria:\n\n* Histologically or cytologically confirmed disease based on the most recent analyzed biopsy metastatic disease that is refractory to or relapsed after at least 2 prior standard-of-care chemotherapy regimens, one of which was a taxane (unless contraindicated).\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior systemic anti-cancer therapy must meet wash-out criteria outlined in protocol\n* Treatment with any high dose systemic corticosteroids or nonsystemic radiotherapy within 2 weeks of the first dose of zamzetoclax (low dose corticosteroids permitted).\n* Women who are pregnant or lactating\n* Patients with active ≥ Grade 2 nausea or vomiting, and/or signs of intestinal obstruction\n* Known active or chronic hepatitis B or C infection or HIV infection/ HIV positive\n* Known history of clinically significant cardiovascular disease or heart failure.\n* Known history of clinically significant active chronic obstructive pulmonary disease or other moderate to severe chronic respiratory illness present within 6 months prior to C1D1\n* Known history of other clinically significant pulmonary disease or evidence of active pneumonitis\n* Uncontrolled pleural effusion, pericardial effusion, or ascites\n* History of clinically significant bleeding, intestinal obstruction, or gastrointestinal (GI) perforation within 6 months prior to C1D1\n* Infection requiring intravenous anti-infective use within 2 weeks prior to C1D1\n* Active or history of autoimmune disease or immune deficiency\n* History of uncured coexisting cancer, not including uncured basal cell carcinoma, cervical cancer in situ, or superficial bladder cancer.\n\nCohort A Specific Exclusion Criteria: zamzetoclax as monotherapy:\n\n* Known heart failure or elevated cardiac biomarkers\n\nCohorts B1 and C1 Specific Exclusion Criteria:\n\n* Known hypersensitivity to excipients in study treatments.\n\nCohorts B4 and C4 Specific Exclusion Criteria:\n\n* Prior treatment with sacituzumab govitecan-hziy or a topoisomerase 1 inhibitor or agents targeting Trop-2.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}